Navigation Links
InteKrin Therapeutics Announces Appointment of Geoffrey M. Parker as Chief Business Officer
Date:7/13/2009

LOS ALTOS, Calif., July 13 /PRNewswire/ -- InteKrin Therapeutics Inc. announced today that Geoffrey M. Parker has joined InteKrin as Chief Business Officer. Most recently, Mr. Parker served as a Managing Director and Partner in the Investment Banking Division of Goldman, Sachs & Co. Over the past ten years, Mr. Parker led Goldman Sachs' West Region Healthcare Investment Banking practice during which time he advised many of the biotechnology industry's leading companies.

"We are very pleased to have such an eminent healthcare business professional join us," said Denny Lanfear, InteKrin Chief Executive. "The expertise, insights and depth of business experience Geoff brings are complementary to the InteKrin team's capabilities as world class drug developers and scientists."

"InteKrin is an exciting opportunity and INT131 presents significant promise for patient benefit," said Geoff. "INT131 has the potential to be a breakthrough product, and I am delighted to be part of the InteKrin team as we complete our Phase 2 work and plan to advance into Phase 3."

About INT131

INT131 is a next-generation insulin sensitizer currently in Phase 2b testing that addresses insulin resistance, a key etiological feature in the onset and subsequent progression of type 2 diabetes. Treating and improving insulin sensitivity in diabetic patients by activating PPAR-gamma is an important therapeutic tool for physicians, providing powerful glucose control and durability of effect. As a SPPARM, INT131 selectively modulates PPAR-gamma, thereby enabling the separation of PPAR gamma anti-diabetic efficacy from the well recognized TZD side effects.

About InteKrin (www.InteKrin.com)

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in-licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.


'/>"/>
SOURCE InteKrin Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
2. InteKrin Therapeutics Announces $20 Million Series C Financing
3. InteKrin Therapeutics Announces INT131 Phase 2a Results at the 2009 American Diabetes Association Annual Meeting
4. Prime Therapeutics Receives TIPPS Certification
5. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
6. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
7. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
8. Deane F. Johnson Center for Neurotherapeutics to Launch First Mobile Medical Unit on October 4th
9. Russell Investment Group Advises Protalix Biotherapeutics of Index Adjustment
10. Adams Respiratory Therapeutics Announces FDA Approval of Grape-Flavored Delsym(R)
11. Prime Therapeutics Announces URAC Accreditation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... Standard Process is ushering in a new era ... North Carolina Research Campus (NCRC) in Kannapolis, North Carolina and by announcing a new ... fall of this year, occupying over 10,000 square feet on the first floor of ...
(Date:7/27/2017)... ... 2017 , ... For bicycling enthusiasts around the globe, Germany's famous Rad am ... against a backdrop of tree-lined hills at the Nürburgring, a Formula One arena known ... Ring consists of some 73 curves, stretching out over more than 500 meters of ...
(Date:7/27/2017)... (PRWEB) , ... July 28, 2017 , ... ... Syngenta on an upcoming episode of the award-winning television series, American Famer, scheduled ... on RFD-TV. , Syngenta is dedicated to helping humanity face its toughest ...
(Date:7/27/2017)... OH (PRWEB) , ... July 27, 2017 , ... ... Electronic Visit Verification to State Medicaid programs, Managed Care Organizations and Home Care ... 2017. , The MEDsys platform, VinCENT, provides technology solutions to over 1,000 agencies ...
(Date:7/27/2017)... ... 2017 , ... GAFFEY Healthcare, a leading provider of revenue ... Vice President of Revenue Cycle Business Services and Suzanne Dusak to Vice President ... officer (CEO). , Elrene has been with company since Oct 2014 and previously ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... 2017 Zymo Research Corp., also known as ,The Epigenetics Company, ... aging in a precise manner using the myDNAge ™ test. Based ... professor of human genetics and biostatistics at the David Geffen School ... , Zymo Research,s proprietary DNAge ™ technology is used to analyze ... ...
(Date:7/11/2017)... JERUSALEM , July 11, 2017 Oramed ... ), a clinical-stage pharmaceutical company focused on the development ... U.S. Food and Drug Administration (FDA) has agreed to ... successfully completed Phase IIb trial of its oral insulin ... The Phase IIb trial met primary and secondary endpoints ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences ... Note to support the development of CRISPR-Cas3 antimicrobial therapeutics. ... Limited, a leading Chinese Internet services provider, and joined ... advance multiple infectious disease product programs targeting antibiotic resistant ... Founded by Dr. Rodolphe Barrangou ...
Breaking Medicine Technology: